LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

8.28 -0.24

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.27

Максимум

8.46

Ключови измерители
By Trading Economics
Приходи	5.1M 5.1M
Продажби	18M 163M
Марж на печалбата	3.113
Служители	580
EBITDA	-84M -62M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+110.59% upside

Дивиденти
By Dow Jones
Следващи печалби	3.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-88M 1.7B
Предишно отваряне	8.52
Предишно затваряне	8.28

Настроения в новините

By Acuity

32%

68%

94 / 371 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.09.2025 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2.09.2025 г., 22:10 ч. UTC

Значими двигатели на пазара

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2.09.2025 г., 21:47 ч. UTC

Печалби

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2.09.2025 г., 16:52 ч. UTC

Значими двигатели на пазара

CleanCore Solutions Shares Drop After $175 Million Private Investment

2.09.2025 г., 22:47 ч. UTC

Пазарно говорене

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2.09.2025 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2.09.2025 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2.09.2025 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2.09.2025 г., 21:05 ч. UTC

Печалби

Couche-Tard 1Q Rev $17.35B >ATD.T

2.09.2025 г., 21:05 ч. UTC

Печалби

Couche-Tard 1Q Adj EPS 78c >ATD.T

2.09.2025 г., 21:05 ч. UTC

Печалби

Couche-Tard 1Q EPS 82c >ATD.T

2.09.2025 г., 21:05 ч. UTC

Печалби

Couche-Tard 1Q Net $782.5M >ATD.T

2.09.2025 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

2.09.2025 г., 20:53 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2.09.2025 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.09.2025 г., 20:27 ч. UTC

Печалби

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2.09.2025 г., 20:24 ч. UTC

Придобивния, сливания и поглъщания

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2.09.2025 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2.09.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2.09.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2.09.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2.09.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2.09.2025 г., 19:55 ч. UTC

Печалби

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2.09.2025 г., 19:50 ч. UTC

Придобивния, сливания и поглъщания

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2.09.2025 г., 19:09 ч. UTC

Пазарно говорене

Oil Futures Gain on Geopolitical Premium -- Market Talk

2.09.2025 г., 19:00 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2.09.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Pushes To New Record -- Market Talk

2.09.2025 г., 17:04 ч. UTC

Пазарно говорене

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2.09.2025 г., 16:57 ч. UTC

Придобивния, сливания и поглъщания

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

110.59% нагоре

12-месечна прогноза

Среден 17.5 USD 110.59%

Висок 30 USD

Нисък 12 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

94 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.